TMCnet News
Research and Markets: Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/9hml8d/twinrix) has announced the addition of the "Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022" report to their offering. Twinrix [Hepatitis A (Inactivated) & Hepatitis B (Recombinant) Vaccine] is GSK's bivalent combination vaccine that protects children, adolescents, and adults against disease caused by HAV and acute and chronic infections caused by all known strains of HBV. Twinrix contains the antigenic components used in GSK's Havrix (formalin-inactivated HAV) and GSK's Engerix-B (yeast-derived recombinant HBsAg) vaccines (Engerix-B package insert, 2013 Havrix package insert, 2012). Scope
Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Overview 3.2 Etiology and Pathophysiology 3.3 Symptoms 4 Vaccination Recommendations and Coverage Rates 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment 6 Twinrix 6.1 Overview 6.2 Immunogenicity 6.3 Safety 6.4 SWOT Analysis 6.5 Forecast 7 Appendix For more information visit http://www.researchandmarkets.com/research/9hml8d/twinrix
|